How to Use Rusfertide
Complete guide to Rusfertide dosing, administration, timing, and protocol recommendations.
Quick Overview
A synthetic hepcidin mimetic peptide developed by Protagonist Therapeutics for managing polycythemia vera (PV). Rusfertide reduces iron availability for red blood cell production, effectively lowering hematocrit levels without phlebotomy. Granted FDA Breakthrough Therapy designation in 2022 and currently in Phase 3 clinical trials.
Dosing Guidelines
Common Dose
40-80 mg weekly
Frequency
Once weekly
Dose Range
10-120 mg weekly (trial range)
Note: Dose titrated based on hematocrit response. In REVIVE trial, most patients stabilized at 40-80 mg weekly. Designed as chronic therapy. Being studied primarily for polycythemia vera but has potential application for TRT-induced erythrocytosis (elevated hematocrit from testosterone therapy).
Administration Method
Subcutaneous injection, once weekly
Best Time to Take
Once weekly, consistent day
Long-acting hepcidin mimetic with weekly dosing schedule. Designed for once-weekly subcutaneous injection for convenience and compliance.
Protocol Duration
Ongoing — designed for chronic use
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Injection site reactions (most common, mild)
- •Iron deficiency (expected mechanism of action)
- •Fatigue
- •Dizziness
- •Headache
Frequently Asked Questions
What is the recommended dose for Rusfertide?
40-80 mg weekly
How do you administer Rusfertide?
Subcutaneous injection, once weekly
When is the best time to take Rusfertide?
Once weekly, consistent day
How long should you use Rusfertide?
Ongoing — designed for chronic use
This information is for educational purposes only. Always consult with a healthcare professional before using any peptide. Dosing information is based on research literature and community reports, not medical advice.